

4240-119

**IN THE CLAIMS:**

Please cancel claim 3 without prejudice.

Please amend claims 1, 4, 9-12, 14, 15, and 19-23 as set forth below.

**Complete Listing of the Claims**

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

1. (Currently amended) A vector for preparing a vaccine which contains one or more than two genes among pgs B, pgs C and pgs A encoding poly- $\gamma$ -glutamate synthetase complex and one or more than two genes selected from human papilloma virus (HPV) E6 and HPV E7 an antigen protein gene of human papilloma virus associated with tumor induction.
2. (Cancelled)
3. (Cancelled)
4. (Currently amended) The vector for preparing a vaccine according to claim 1, in which pgs A gene encoding saidthe poly- $\gamma$ -glutamate synthetase complex is contained.
5. (Cancelled)
6. (Cancelled)
7. (Original) A Gram positive microbe which is transformed with the vector for preparing a vaccine of claim 1.
8. (Original) The microbe according to claim 7, in which said microbe is selected from a group comprising *Bacillus*, *Lactobacillus*, *Lactococcus*, *Staphylococcus*, *Lysteria*, *Monocytogenesis*, and *Streptococcus*.
9. (Currently amended) A vaccine for treating or preventing a mucosal tumor, which contains as an effective component, microbes a microbe transformed with the vector of claim 1, expressing one or more of HPV E6 and HPV E7 an antigen protein onto a cell surface, erude antigen proteins the extract from said microbes or antigen proteins purified from said microbes.
10. (Currently amended) The vaccine for treating or preventing a mucosal tumor according to claim 9, which can be administered orally or be edible.

4240-119

11. (Currently amended) The vaccine for treating or preventing a mucousmucosal tumor according to claim 9, which can be injected subcutaneously or peritoneally.

12. (Currently amended) The vaccine for treating or preventing a mucosal tumor according to claim 9, which can be sprayed to the nasal cavity.

13. (Cancelled)

14. (Currently amended) The vector for preparing a vaccine according to claim 1, comprising pgs C, pgs A and HPV E7 genes and wherein the vector is which has the genetic map as illustrated in Fig. 5 and is named as pHCE2LB: pgsBCA- HPV E7.

15. (Currently amended) A microbe which is transformed with the pHCE2LB: pgsBCA- HPV E7 vector.

16. (Previously presented) The microbe according to claim 15, in which *Lactobacillus* is used as a host cell.

17. (Cancelled).

18. (Previously presented) The *Escherichia coli* transformant identified by accession number: KCTC 10520 BP.

19. (Currently amended) A vaccine for treating or preventing a mucosal tumor which includes as an effective component, the microbe of claim 16 expressing an HPV E7 antigen protein onto a cell surface, crude antigen proteins the extract from said microbe or antigen proteins protein purified from said microbe.

20. (Currently amended) The vaccine for treating or preventing a mucosal tumor according to claim 19, which can be administered orally or be edible.

21. (Currently amended) The vaccine for treating or preventing a mucosal tumor according to claim 19, which can be injected subcutaneously or peritoneally.

22. (Currently amended) The vaccine for treating or preventing a mucosal tumor according to claim 19, which can be sprayed to the nasal cavity.

4240-119

23. (Currently amended) A washing solution for a genital organ, which includes as an effective component, the microbe of claim 16 expressing an HPV E7 antigen protein onto a cell surface, ~~crude antigen proteins~~ the extract from said microbe or antigen proteins protein purified from said microbe.

**THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK**